CN107922404B - 氯喹和克立咪唑化合物用于治疗炎症和癌症的用途 - Google Patents

氯喹和克立咪唑化合物用于治疗炎症和癌症的用途 Download PDF

Info

Publication number
CN107922404B
CN107922404B CN201680039155.3A CN201680039155A CN107922404B CN 107922404 B CN107922404 B CN 107922404B CN 201680039155 A CN201680039155 A CN 201680039155A CN 107922404 B CN107922404 B CN 107922404B
Authority
CN
China
Prior art keywords
clemizole
chloroquine
liver
compound
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680039155.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN107922404A (zh
Inventor
J·S·格伦
E·A·彭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eiger Group International Inc
Original Assignee
Eiger Group International Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eiger Group International Inc filed Critical Eiger Group International Inc
Priority to CN202110651428.2A priority Critical patent/CN113274386A/zh
Publication of CN107922404A publication Critical patent/CN107922404A/zh
Application granted granted Critical
Publication of CN107922404B publication Critical patent/CN107922404B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201680039155.3A 2015-06-30 2016-06-30 氯喹和克立咪唑化合物用于治疗炎症和癌症的用途 Active CN107922404B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110651428.2A CN113274386A (zh) 2015-06-30 2016-06-30 氯喹和克立咪唑化合物用于治疗炎症和癌症的用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562187061P 2015-06-30 2015-06-30
US62/187,061 2015-06-30
PCT/US2016/040566 WO2017004454A1 (en) 2015-06-30 2016-06-30 Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202110651428.2A Division CN113274386A (zh) 2015-06-30 2016-06-30 氯喹和克立咪唑化合物用于治疗炎症和癌症的用途

Publications (2)

Publication Number Publication Date
CN107922404A CN107922404A (zh) 2018-04-17
CN107922404B true CN107922404B (zh) 2021-06-29

Family

ID=57609247

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201680039155.3A Active CN107922404B (zh) 2015-06-30 2016-06-30 氯喹和克立咪唑化合物用于治疗炎症和癌症的用途
CN202110651428.2A Pending CN113274386A (zh) 2015-06-30 2016-06-30 氯喹和克立咪唑化合物用于治疗炎症和癌症的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202110651428.2A Pending CN113274386A (zh) 2015-06-30 2016-06-30 氯喹和克立咪唑化合物用于治疗炎症和癌症的用途

Country Status (14)

Country Link
US (3) US10688083B2 (https=)
EP (1) EP3317274A4 (https=)
JP (3) JP7068827B2 (https=)
KR (2) KR20180032578A (https=)
CN (2) CN107922404B (https=)
AU (4) AU2016288699B2 (https=)
CA (3) CA2989634C (https=)
HK (1) HK1249508A1 (https=)
IL (4) IL300476B2 (https=)
MX (3) MX394605B (https=)
NZ (1) NZ776616A (https=)
TW (3) TWI771272B (https=)
WO (1) WO2017004454A1 (https=)
ZA (2) ZA201708471B (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL300476B2 (en) * 2015-06-30 2024-07-01 Eiger Group Int Inc Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
GB201702160D0 (en) 2017-02-09 2017-03-29 Univ Leeds Innovations Ltd Inhibitors for use in therapy
CN106831571A (zh) * 2017-02-13 2017-06-13 中卫市创科知识产权投资有限公司 一种硫酸氯喹生产工艺
US12372530B2 (en) * 2017-11-15 2025-07-29 Beth Israel Deaconess Medical Center, Inc. Markers for the diagnosis and treatment of non-alcoholic steatohepatitis (NASH) and advanced liver fibrosis
CN113354581B (zh) * 2020-03-06 2023-06-20 华南理工大学 手性氯喹及其磷酸盐的制备方法及其应用
CN113527201A (zh) * 2020-04-14 2021-10-22 瀚海新拓(杭州)生物医药有限公司 光学活性氯喹和羟氯喹及其类似物、其制备方法、组合物和用途
WO2021217574A1 (en) * 2020-04-30 2021-11-04 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Treatment or prevention of coronaviridae infection
CN111551645B (zh) * 2020-04-30 2022-11-08 上海中西三维药业有限公司 一种硫酸羟氯喹有关物质的检测方法及其应用
CN111909087A (zh) * 2020-06-15 2020-11-10 珠海润都制药股份有限公司 一种手性氨基氯喹啉的制备方法
CN111662229B (zh) * 2020-07-08 2023-03-24 精华制药集团南通有限公司 一种磷酸氯喹的制备工艺
CN111793026A (zh) * 2020-07-23 2020-10-20 珠海润都制药股份有限公司 一种硫酸羟氯喹及其对映体的晶型和制备方法
CN114057640A (zh) * 2020-08-05 2022-02-18 凯特立斯（深圳）科技有限公司 一种光学纯(r)/(s)-羟氯喹侧链的不对称合成方法
CN112225697B (zh) * 2020-10-16 2023-01-03 宁波大学 一种对映体纯氯喹及磷酸氯喹的制备方法
CN114573464A (zh) * 2022-03-02 2022-06-03 重庆南松凯博生物制药有限公司 一种羟氯喹侧链精制方法
CN116327749A (zh) * 2023-04-21 2023-06-27 重庆医科大学 Gw9662制备治疗非酒精性脂肪性肝炎药物的应用

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181725A (en) * 1977-05-02 1980-01-01 The Regents Of The University Of Michigan Method for alleviating psoriasis
WO1998017231A2 (en) 1996-10-18 1998-04-30 Charous B Lauren Treatment and delivery of hydroxychloroquine
CA2372443C (en) 1999-04-30 2010-07-13 Apt Pharmaceuticals, L.L.C. Local administration of anti-malarial agents for the treatment of inflammatory diseases
US20060014786A1 (en) * 2002-05-17 2006-01-19 Rajeev Raut Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
US20040009949A1 (en) 2002-06-05 2004-01-15 Coley Pharmaceutical Group, Inc. Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory CpG nucleic acids
ZA200505996B (en) * 2003-02-14 2006-12-27 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
TW200509958A (en) 2003-02-14 2005-03-16 Combinatorx Inc Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
WO2004080445A1 (en) 2003-03-12 2004-09-23 Molecular Engines Laboratories Sa Methods and compositions for the treatment of cancer
US20050192261A1 (en) 2003-09-15 2005-09-01 Jost-Price Edward R. Methods and reagents for the treatment of immunoinflammatory disorders
JP2007509950A (ja) * 2003-10-27 2007-04-19 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｈｃｖ処置の組合せ剤
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
CN101193622A (zh) 2005-06-09 2008-06-04 比奥里波克斯公司 治疗炎性疾病的方法和组合物
PL1888033T3 (pl) * 2005-06-09 2014-09-30 Meda Ab Sposób i kompozycja do leczenia chorób zapalnych
MX2008010355A (es) * 2006-02-09 2008-10-31 Schering Corp Combinaciones que comprenden inhibidores de proteasa del virus de la hepatitis c e inhibidores de polimerasa del virus de la hepatitis c, y metodos de tratamiento relacionados con los mismos.
JP5715820B2 (ja) * 2007-09-18 2015-05-13 スタンフォード ユニバーシティー フラビウイルス科ファミリーのウイルスへの感染を治療する方法ならびに、フラビウイルス科ファミリーのウイルスへの感染を治療するための組成物
US9101628B2 (en) * 2007-09-18 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Methods and composition of treating a flaviviridae family viral infection
US20120114670A1 (en) 2007-10-02 2012-05-10 University Of Rochester Methods and compositions related to synergistic responses to oncogenic mutations
EP2188630A4 (en) * 2007-10-02 2010-11-03 Univ Rochester METHODS AND COMPOSITIONS RELATED TO SYNERGISTIC ANSWERS TO ONCOGENIC MUTATIONS
US20120082659A1 (en) * 2007-10-02 2012-04-05 Hartmut Land Methods And Compositions Related To Synergistic Responses To Oncogenic Mutations
CL2009000647A1 (es) 2008-04-04 2010-06-04 Chugai Pharmaceutical Co Ltd Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders
EP2408449A4 (en) * 2009-03-18 2012-08-08 Univ Leland Stanford Junior METHOD AND COMPOSITIONS FOR TREATING FLAVIVIRIDAE VIRUS INFECTIONS
MX373926B (es) * 2009-05-27 2020-07-10 Ptc Therapeutics Inc Metodos para tratar cancer y estados no neoplasicos.
KR20120039742A (ko) 2009-07-31 2012-04-25 가부시끼가이샤 스텔릭 사이세이 이카가꾸 겐뀨쇼 지방성 간염-간암 모델 동물
ES2767881T3 (es) * 2009-08-14 2020-06-18 Revivicor Inc Cerdos multi-transgénicos para el tratamiento de diabetes
US9415046B2 (en) 2009-09-29 2016-08-16 Yale University Compositions and methods for inhibiting inflammation from and rejection of biomaterials and other methods
US20120202849A1 (en) 2009-10-12 2012-08-09 Anil Pareek Pharmaceutical compositions for the treatment/prophylaxis of non-alcoholic fatty liver disease
US9700560B2 (en) 2009-11-16 2017-07-11 University Of Georgia Research Foundation, Inc. 2′-fluoro-6′-methylene carbocyclic nucleosides and methods of treating viral infections
MX360979B (es) * 2011-09-16 2018-11-22 Galectin Therapeutics Inc Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y de la enfermedad del higado graso no alcohólico.
EP2818473A4 (en) 2012-02-20 2015-04-15 Takeda Pharmaceutical HETEROCYCLIC CONNECTION
US20130273003A1 (en) 2012-04-17 2013-10-17 Vertex Pharmaceuticals Incorporated Therapies for Treating Hepatitis C Virus Infection
JP6165848B2 (ja) * 2012-05-22 2017-07-19 イデニク ファーマシューティカルズ エルエルシー 肝疾患のためのｄ−アミノ酸化合物
TW201402556A (zh) * 2012-05-30 2014-01-16 Toyama Chemical Co Ltd 氘化含氮雜環羧醯胺衍生物或其鹽
WO2014031769A2 (en) 2012-08-21 2014-02-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of diseases associated with inflammation
JP6146990B2 (ja) * 2012-11-16 2017-06-14 コンサート ファーマシューティカルズ インコーポレイテッド 重水素化されたｃｆｔｒ増強物質
CN103550242B (zh) * 2013-11-22 2015-07-15 四川国康药业有限公司 一种治疗肝纤维化的药物组合物及其制备方法
CN105934438A (zh) 2013-11-27 2016-09-07 艾登尼克斯药业有限公司 用于治疗肝癌的核苷酸
JP6367545B2 (ja) * 2013-12-17 2018-08-01 コンサート ファーマシューティカルズ インコーポレイテッド ルキソリチニブの重水素化誘導体
IL300476B2 (en) * 2015-06-30 2024-07-01 Eiger Group Int Inc Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions

Also Published As

Publication number Publication date
AU2021201234A1 (en) 2021-03-11
IL279020A (https=) 2020-12-31
TW201717941A (zh) 2017-06-01
BR112017028601A2 (pt) 2018-08-28
CA3178499A1 (en) 2017-01-05
JP2024083475A (ja) 2024-06-21
US20240398761A1 (en) 2024-12-05
AU2024266943A1 (en) 2024-12-19
IL279020B1 (en) 2023-03-01
KR20230129590A (ko) 2023-09-08
MX394605B (es) 2025-03-24
HK1249508A1 (zh) 2018-11-02
IL300476B1 (en) 2024-03-01
EP3317274A4 (en) 2019-05-08
MX2023003792A (es) 2023-04-26
TWI881480B (zh) 2025-04-21
IL300476B2 (en) 2024-07-01
JP7470151B2 (ja) 2024-04-17
KR20180032578A (ko) 2018-03-30
CN107922404A (zh) 2018-04-17
CA2989634A1 (en) 2017-01-05
IL310969A (en) 2024-04-01
EP3317274A1 (en) 2018-05-09
WO2017004454A8 (en) 2018-01-25
US20180200228A1 (en) 2018-07-19
JP7810746B2 (ja) 2026-02-03
JP7068827B2 (ja) 2022-05-17
TW202317103A (zh) 2023-05-01
CN113274386A (zh) 2021-08-20
US12090141B2 (en) 2024-09-17
JP2018519340A (ja) 2018-07-19
MX2017016681A (es) 2018-07-06
IL300476A (en) 2023-04-01
AU2016288699B2 (en) 2020-11-26
AU2016288699A1 (en) 2018-01-18
NZ776616A (en) 2024-11-29
ZA202004136B (en) 2025-08-27
TWI830262B (zh) 2024-01-21
ZA201708471B (en) 2022-05-25
TW202402283A (zh) 2024-01-16
TWI771272B (zh) 2022-07-21
MX2022008100A (es) 2022-07-11
CA3294570A1 (en) 2026-03-02
JP2022105149A (ja) 2022-07-12
WO2017004454A1 (en) 2017-01-05
NZ738291A (en) 2021-06-25
IL279020B2 (en) 2023-07-01
IL256233A (en) 2018-02-28
US10688083B2 (en) 2020-06-23
AU2023201397B2 (en) 2024-10-03
US20210052553A1 (en) 2021-02-25
CA2989634C (en) 2022-12-06
AU2023201397A1 (en) 2023-04-06

Similar Documents

Publication Publication Date Title
CN107922404B (zh) 氯喹和克立咪唑化合物用于治疗炎症和癌症的用途
CN108290911B (zh) (r)-及(s)-1-(3-(3-n,n-二甲基胺基羰基)苯氧基-4-硝苯基)-1-乙基-n,n’-双(伸乙基)胺基磷酸酯、组合物及其使用及制备方法
US20190031613A1 (en) Compounds and methods for their use in the treatment of malaria
NZ738291B2 (en) Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
KR20130100574A (ko) 알콕시페닐프로펜온 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 다약제 내성 억제용 약학적 조성물
BR112017028601B1 (pt) Uso de clemizol

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant